Gilead Sciences's Options: A Look at What the Big Money is Thinking - Gilead Sciences ( NASDAQ:GILD )
Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences ( NASDAQ:GILD ) . We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we ...
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences Inc. ( NASDAQ:GILD ) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen ...
2 Supercharged Dividend Stocks to Buy Now
Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - CoreWeave ( NASDAQ:CRWV ) , CPS Technologies ( NASDAQ:CPSH )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden ...
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Invesco Pharmaceuticals ETF ( PJP ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences Inc. ( NASDAQ:GILD ) announced on Friday data from the Phase 3 ASCENT-07 study of Trodelvy ( sacituzumab govitecan-hziy ) versus chemotherapy in HR+/HER2-negative metastatic breast cancer patients.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
Immuthera, operating in the United States, is a wholly owned subsidiary of PolTREG S.A. a leader in innovative immune therapies with focus on regulatory T cell technologies. In addition, Dr. Bot will serve as Scientific Advisor of PolTREG S.A., leveraging his experience in development and ...
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies Dr. Adrian Bot, a renowned biopharmaceutical founder and scientist, has joined Immuthera's Board of Directors to strengthen its pipeline development and ...
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® - Assembly Biosciences ( NASDAQ:ASMB )
- Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation -
Is Trending Stock Gilead Sciences, Inc. ( GILD ) a Buy Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
CAMBRIDGE, Mass., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc. ( Nasdaq: PRME ) , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business ...
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Highly experienced biopharma financial officer joins leadership team ...
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences Inc ( NASDAQ:GILD ) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13. The U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion.
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Gilead GILD Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, October 30, 2025 at 4:30 p.m. ETChairman and Chief Executive Officer - Daniel P. O'DayContinue reading ...
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
NEW YORK and VIENNA, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( OTCID: HOOK, "HOOKIPA" ) today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and certain of its assets related to HOOKIPA's HB-500 program to Gilead Sciences, Inc. ( "Gilead" ) ...
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - HOOKIPA Pharma ( OTC:HOOK )
NEW YORK and VIENNA, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( OTCID: HOOK, "HOOKIPA" ) today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and certain of its assets related to HOOKIPA's HB-500 program to Gilead Sciences, Inc. ( "Gilead" ) ...
3 Healthcare Mutual Funds to Buy for Attractive Returns
Below, we share with you three top-ranked healthcare mutual funds. Each has earned a Zacks Mutual Fund Rank #1.
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?
Venture capital fund Third Rock Ventures IV, L.P., a 10% owner of Tango Therapeutics, Inc. ( NASDAQ:TNGX ) , reported the sale of 477,401 shares in an open-market transaction on October 23, 2025, according to an SEC Form 4 filing.Transaction value is based on the SEC Form 4 weighted average ...
Gilead Sciences ( GILD ) Q3 Earnings and Revenues Top Estimates
Gilead (GILD) delivered earnings and revenue surprises of +14.88% and +4.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics to Participate in Upcoming Investor Conferences - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T.
CVS Health Stock Hits 52 Week High - CVS Health ( NYSE:CVS )
CVS Health Corp ( NYSE:CVS ) on Wednesday reported better-than-expected third-quarter earnings and raised its annual guidance. The company reported sales of $102.87 billion, beating the consensus of $98.84 billion. Total revenues increased 7.8% year-over-year, driven by revenue growth across ...
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
Earnings Preview: AC Immune ( ACIU ) Q3 Earnings Expected to Decline
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences ( NASDAQ:GILD ) has outperformed the market over the past 20 years by 2.91% on an annualized basis producing an average annual return of 11.89%. Currently, Gilead Sciences has a market capitalization of $149.13 billion.
Top Stocks With Earnings This Week: SoFi, Apple, Meta and More - SoFi Technologies ( NASDAQ:SOFI )
Individual investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. Here's a look at the reports Wall Street and investors will be watching. SOFI stock is moving. See the real-time price action here.
Curious about Gilead ( GILD ) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
SAN FRANCISCO, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the ...
Gilead Sciences ( GILD ) Earnings Expected to Grow: Should You Buy?
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences ( GILD ) Falls More Steeply Than Broader Market: What Investors Need to Know
Gilead Sciences (GILD) concluded the recent trading session at $121.46, signifying a -2.11% move from its prior day's close.
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
SAN FRANCISCO, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the ...
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia ...
Aisera Leads the Shift to Autonomous IT, Bringing Enterprises Closer Than Ever to True Self-Service with Agentic AI
SANTA CLARA, Calif., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- Aisera, the leading provider of agentic AI for the enterprise, continues to evolve its agentic capabilities for end-user self-service and autonomous IT, building on its position as the recognized industry leader in this category.
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology ( ESMO ) Congress
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies ...
Gene Siskel Film Center of the School of the Art Institute of Chicago Announces Full Program for the 31st Annual Black Harvest Film Festival
Festival lineup includes eight feature films and nine shorts, film awards, a Community Film Workshop, Mystery Movie Monday, and BLKNWS
Gilead Sciences, Inc. ( GILD ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Ligand to Host Investor Day on December 9, 2025 - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND ) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30 a.m. to 12:00 p.m. Eastern Time at The Harvard Club.
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
VEEV's strong Q2, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials - Merck & Co ( NYSE:MRK )
The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management.
Assembly Biosciences Announces Upcoming Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- Assembly Biosciences, Inc. ( Nasdaq: ASMB ) , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will participate in fireside chats at two upcoming investor ...
Assembly Biosciences Announces Upcoming Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- Assembly Biosciences, Inc. ( Nasdaq: ASMB ) , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will participate in fireside chats at two upcoming investor ...
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Arcus Biosciences ( NYSE:RCUS ) , Gilead Sciences ( NASDAQ:GILD )
On Sunday, Arcus Biosciences Inc. ( NYSE:RCUS ) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
